Stock listing
KRX:311690 CJ Bioscience. Inc. (CJ 바이오사이언스) 주가
Follow CJ Bioscience. Inc. into a list and get an email when it puts out news.
Share price · KRX:311690
₩3,330.00 KRW -70.00 (-2.1%)
Close on Nov 20, 2026
- Day range
- ₩3,200.00 – ₩3,365.00 KRWNov 20, 2026
- Volume
- 969 sharesNov 20, 2026
- Market cap
- ₩43.51B KRWAt the close on Nov 20, 2026 · price × 13.07M shares outstanding
- 52-week range
- ₩3,060.00 – ₩10,200.00 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩23.85M KRWMedian day 5,067 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:311690 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩3,330.00 | -70.00 | -2.1% | ₩3,365.00 | ₩3,365.00 | ₩3,200.00 | 969 | |
| ₩3,400.00 | -95.00 | -2.7% | ₩3,460.00 | ₩3,560.00 | ₩3,315.00 | 5,026 | |
| ₩3,495.00 | -50.00 | -1.4% | ₩3,440.00 | ₩3,515.00 | ₩3,360.00 | 2,099 | |
| ₩3,545.00 | -5.00 | -0.1% | ₩3,630.00 | ₩3,630.00 | ₩3,360.00 | 2,772 | |
| ₩3,550.00 | +50.00 | +1.4% | ₩3,490.00 | ₩3,590.00 | ₩3,310.00 | 10,725 | |
| ₩3,500.00 | -30.00 | -0.8% | ₩3,505.00 | ₩3,600.00 | ₩3,370.00 | 6,583 | |
| ₩3,530.00 | -15.00 | -0.4% | ₩3,480.00 | ₩3,630.00 | ₩3,455.00 | 5,757 | |
| ₩3,545.00 | +70.00 | +2.0% | ₩3,515.00 | ₩3,620.00 | ₩3,480.00 | 8,128 | |
| ₩3,475.00 | -15.00 | -0.4% | ₩3,490.00 | ₩3,545.00 | ₩3,400.00 | 3,887 | |
| ₩3,490.00 | -160.00 | -4.4% | ₩3,585.00 | ₩3,585.00 | ₩3,400.00 | 17,728 | |
| ₩3,650.00 | -65.00 | -1.7% | ₩3,830.00 | ₩3,850.00 | ₩3,630.00 | 39,227 | |
| ₩3,715.00 | +30.00 | +0.8% | ₩3,845.00 | ₩3,845.00 | ₩3,610.00 | 7,501 | |
| ₩3,685.00 | +10.00 | +0.3% | ₩3,650.00 | ₩3,765.00 | ₩3,610.00 | 8,884 | |
| ₩3,675.00 | -20.00 | -0.5% | ₩3,695.00 | ₩3,865.00 | ₩3,650.00 | 10,339 | |
| ₩3,695.00 | +5.00 | +0.1% | ₩3,630.00 | ₩3,800.00 | ₩3,615.00 | 3,033 | |
| ₩3,690.00 | +40.00 | +1.1% | ₩3,640.00 | ₩3,980.00 | ₩3,500.00 | 5,679 | |
| ₩3,650.00 | +10.00 | +0.3% | ₩3,700.00 | ₩3,870.00 | ₩3,640.00 | 2,215 | |
| ₩3,640.00 | -45.00 | -1.2% | ₩3,800.00 | ₩3,910.00 | ₩3,630.00 | 5,844 | |
| ₩3,685.00 | +80.00 | +2.2% | ₩3,705.00 | ₩3,730.00 | ₩3,595.00 | 17,718 | |
| ₩3,605.00 | -85.00 | -2.3% | ₩3,945.00 | ₩3,945.00 | ₩3,600.00 | 7,943 | |
| ₩3,690.00 | -85.00 | -2.3% | ₩3,710.00 | ₩3,820.00 | ₩3,690.00 | 1,944 | |
| ₩3,775.00 | +55.00 | +1.5% | ₩3,720.00 | ₩3,900.00 | ₩3,645.00 | 3,333 | |
| ₩3,720.00 | 0.00 | 0.0% | ₩3,795.00 | ₩3,795.00 | ₩3,605.00 | 4,752 | |
| ₩3,720.00 | +20.00 | +0.5% | ₩4,035.00 | ₩4,035.00 | ₩3,660.00 | 2,502 | |
| ₩3,700.00 | 0.00 | 0.0% | ₩3,610.00 | ₩3,925.00 | ₩3,610.00 | 3,916 | |
| ₩3,700.00 | +15.00 | +0.4% | ₩3,950.00 | ₩3,950.00 | ₩3,627.00 | 11,389 | |
| ₩3,685.00 | -5.00 | -0.1% | ₩3,690.00 | ₩3,905.00 | ₩3,685.00 | 5,833 | |
| ₩3,690.00 | -5.00 | -0.1% | ₩3,695.00 | ₩3,725.00 | ₩3,515.00 | 4,479 | |
| ₩3,695.00 | -150.00 | -3.9% | ₩3,845.00 | ₩3,890.00 | ₩3,695.00 | 16,883 | |
| ₩3,845.00 | +25.00 | +0.7% | ₩3,880.00 | ₩3,950.00 | ₩3,820.00 | 9,177 | |
| ₩3,820.00 | +80.00 | +2.1% | ₩3,715.00 | ₩3,835.00 | ₩3,695.00 | 6,013 | |
| ₩3,740.00 | -35.00 | -0.9% | ₩3,775.00 | ₩3,795.00 | ₩3,705.00 | 4,403 | |
| ₩3,775.00 | +45.00 | +1.2% | ₩3,800.00 | ₩3,800.00 | ₩3,700.00 | 6,703 | |
| ₩3,730.00 | +25.00 | +0.7% | ₩3,705.00 | ₩3,830.00 | ₩3,685.00 | 4,221 | |
| ₩3,705.00 | -25.00 | -0.7% | ₩3,720.00 | ₩3,750.00 | ₩3,690.00 | 2,117 | |
| ₩3,730.00 | -10.00 | -0.3% | ₩3,745.00 | ₩3,860.00 | ₩3,650.00 | 7,231 | |
| ₩3,740.00 | +30.00 | +0.8% | ₩3,800.00 | ₩3,800.00 | ₩3,615.00 | 8,214 | |
| ₩3,710.00 | +5.00 | +0.1% | ₩3,795.00 | ₩3,795.00 | ₩3,595.00 | 6,900 | |
| ₩3,705.00 | +75.00 | +2.1% | ₩3,800.00 | ₩3,800.00 | ₩3,665.00 | 3,586 | |
| ₩3,630.00 | -15.00 | -0.4% | ₩3,685.00 | ₩3,800.00 | ₩3,625.00 | 6,344 | |
| ₩3,645.00 | -35.00 | -1.0% | ₩3,685.00 | ₩3,715.00 | ₩3,645.00 | 5,108 | |
| ₩3,680.00 | -15.00 | -0.4% | ₩3,865.00 | ₩3,870.00 | ₩3,615.00 | 4,460 | |
| ₩3,695.00 | -5.00 | -0.1% | ₩3,715.00 | ₩3,850.00 | ₩3,660.00 | 6,322 | |
| ₩3,700.00 | -135.00 | -3.5% | ₩3,720.00 | ₩3,845.00 | ₩3,595.00 | 3,647 | |
| ₩3,835.00 | -20.00 | -0.5% | ₩3,855.00 | ₩3,970.00 | ₩3,730.00 | 3,555 | |
| ₩3,855.00 | 0.00 | 0.0% | ₩3,855.00 | ₩3,995.00 | ₩3,805.00 | 3,359 | |
| ₩3,855.00 | -115.00 | -2.9% | ₩3,980.00 | ₩3,980.00 | ₩3,830.00 | 1,598 | |
| ₩3,970.00 | +75.00 | +1.9% | ₩3,990.00 | ₩3,990.00 | ₩3,790.00 | 2,968 | |
| ₩3,895.00 | -125.00 | -3.1% | ₩3,990.00 | ₩4,020.00 | ₩3,895.00 | 3,324 | |
| ₩4,020.00 | +35.00 | +0.9% | ₩3,990.00 | ₩4,070.00 | ₩3,895.00 | 2,488 | |
| ₩3,985.00 | -5.00 | -0.1% | ₩3,990.00 | ₩4,000.00 | ₩3,935.00 | 2,694 | |
| ₩3,990.00 | -110.00 | -2.7% | ₩4,070.00 | ₩4,095.00 | ₩3,990.00 | 4,285 | |
| ₩4,100.00 | +15.00 | +0.4% | ₩4,090.00 | ₩4,180.00 | ₩3,970.00 | 11,390 | |
| ₩4,085.00 | +15.00 | +0.4% | ₩4,070.00 | ₩4,185.00 | ₩4,000.00 | 5,566 | |
| ₩4,070.00 | -30.00 | -0.7% | ₩4,100.00 | ₩4,150.00 | ₩4,000.00 | 2,498 | |
| ₩4,100.00 | +135.00 | +3.4% | ₩3,965.00 | ₩4,150.00 | ₩3,965.00 | 10,602 | |
| ₩3,965.00 | +115.00 | +3.0% | ₩4,000.00 | ₩4,030.00 | ₩3,900.00 | 9,059 | |
| ₩3,850.00 | +40.00 | +1.0% | ₩3,950.00 | ₩3,950.00 | ₩3,820.00 | 1,309 | |
| ₩3,810.00 | -85.00 | -2.2% | ₩4,000.00 | ₩4,000.00 | ₩3,720.00 | 2,023 | |
| ₩3,895.00 | +200.00 | +5.4% | ₩3,695.00 | ₩4,005.00 | ₩3,600.00 | 10,657 | |
| ₩3,695.00 | -155.00 | -4.0% | ₩3,950.00 | ₩3,950.00 | ₩3,650.00 | 5,359 | |
| ₩3,850.00 | +55.00 | +1.4% | ₩3,995.00 | ₩3,995.00 | ₩3,795.00 | 2,840 |
Splits
1 split · KRX:311690 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 65-for-57 | Split |
- Ticker
- KRX:311690
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
Latest news
CJ Bioscience. Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 1 in all · newest Feb 18, 2025 · oldest 2025
Valuation
EV/sales 0.7× against a median of 7.3×: 2nd lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩2.56B KRW
- P/E
- Loss
- EV/sales
- 0.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.0×
- Gross margin
- 21.4%
- Operating margin
- −624.9%
- Net margin
- −607.2%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CJ Bioscience. Inc. · KRX:311690 | US$32.32M | US$1.90M | n/a | 0.7× | n/a | 1.0× | −607.2% | 0.0× | n/a |
| B&K Corporation Limited Class H · HKEX:2396 | US$33.15M | −US$47.28M | n/a | −603× | n/a | 0.4× | n/a | 0.0× | n/a |
| Veru Inc. · NASDAQ:VERU | US$33.08M | US$9.20M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.92 |
| Actinium Pharmaceuticals, Inc. (Delaware) · AMEX:ATNM | US$33.01M | US$5.49M | 3.1× | n/a | 0.6× | 1.3× | n/a | 0.1× | 0.71 |
| Neurizon Therapeutics Limited · ASX:NUZ | US$32.76M | US$26.54M | n/a | 2.3× | n/a | 3.9× | −61.0% | 0.3× | n/a |
| Transcenta Holding Limited · HKEX:6628 | US$32.41M | US$52.57M | n/a | 12.4× | n/a | 0.4× | −569.5% | 0.3× | n/a |
| Enimmune Corporation · TPEX:6564 | US$31.73M | US$26.87M | n/a | 18.4× | n/a | 10.4× | −341.0% | 0.3× | n/a |
| Molecure SA · GPW:MOC | US$31.67M | US$29.61M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Isofol Medical AB · OMXSTO:ISOFOL | US$31.07M | US$19.83M | n/a | n/a | n/a | 3.3× | n/a | 0.0× | n/a |
| Sareum Holdings plc · LSE:SAR | US$31.03M | US$27.78M | n/a | n/a | n/a | 19.9× | n/a | 0.0× | n/a |
| Filana Therapeutics, Inc. · NASDAQ:FLNA | US$30.98M | −US$16.01M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.25 |
| Median of the others | US$32.07M | US$23.18M | 3.1× | 7.3× | 0.6× | 1.3× | −341.0% | 0.0× | 1.25 |
Team and board
| Officer | Role |
|---|---|
| Chalita Williams | Chief Executive Officer |
| Mauricio Anto | Chief Operating Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 28, 2024 · Before open | −2.8% |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.69B | 3.47B | 5.58B | 4.07B | 4.36B | 5.31B | 4.78B | 3.92B | 3.67B |
| Cost of revenue | 2.99B | 3.10B | 3.73B | 2.67B | 2.71B | 2.90B | 2.11B | 1.73B | 1.79B |
| Gross profit | 698.9M | 365.4M | 1.84B | 1.41B | 1.65B | 2.41B | 2.67B | 2.20B | 1.88B |
| Research and development | 18.1B | 23.2B | 22.8B | 19.2B | 4.85B | 4.98B | 3.40B | ||
| Selling, general and administrative | 1.84B | 10.2B | 9.95B | 13.4B | 6.13B | 5.57B | 3.48B | 3.19B | 2.27B |
| Operating income | -24.8B | -34.2B | -32.0B | -33.2B | -12.2B | -8.51B | -4.52B | -3.41B | -2.62B |
| Depreciation and amortization | 4.01B | 4.28B | 5.11B | 3.90B | 1.56B | 1.05B | 731.0M | 439.1M | 500.2M |
| EBITDA | -20.8B | -30.0B | -26.9B | -29.3B | -10.7B | -7.46B | -3.79B | -2.97B | -2.12B |
| Interest expense | 540.2M | 587.4M | 922.1M | 2.76B | 4.97B | 1.62B | 45.3M | 0 | 0 |
| Income before tax | -24.0B | -32.8B | -22.9B | -34.9B | -19.3B | -8.76B | -4.35B | -3.13B | -2.36B |
| Net income | -24.0B | -32.8B | -22.9B | -34.9B | -19.3B | -8.76B | -4.35B | -3.13B | -2.36B |
| Earnings per share, basic | -1,837.29 | -2,513.32 | -2,514.44 | -5,939.00 | -2,815.87 | -2,251.23 | -1,140.92 | -973.88 | -735.99 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 10.3B | 8.31B | 64.1B | 49.3B | 62.1B | 13.3B | 5.33B | 148.6K | 178.8K |
| Short-term investments | 40.5B | 67.0B | 18.0B | 26.0B | 25.7B | 20.0M | 20.0M | ||
| Receivables | 418.8M | 334.1M | 303.5M | 303.8M | 233.6M | 99.5M | 194.1M | 301.3M | 258.3M |
| Inventory | 185.1M | 128.8M | 157.8M | 76.2M | 145.8M | 364.3M | 98.7M | 145.8M | 111.6M |
| Current assets | 52.5B | 76.8B | 65.2B | 50.9B | 81.6B | 41.1B | 31.6B | 11.5B | 13.4B |
| Property, plant and equipment | 8.91B | 12.7B | 14.4B | 9.86B | 20.0B | 1.73B | 920.8M | 1.25B | |
| Total assets | 72.3B | 99.6B | 91.1B | 91.4B | 116.4B | 73.4B | 33.7B | 12.8B | 15.0B |
| Accounts payable | 378.3M | 220.8M | 122.8M | 336.7M | 287.7M | 708.9M | 288.9M | ||
| Current liabilities | 14.6B | 18.5B | 14.7B | 35.0B | 23.8B | 3.00B | 2.31B | 1.88B | 1.62B |
| Long-term debt | 0 | 0 | 35.1B | ||||||
| Total debt | 35.6B | 368.2M | |||||||
| Total liabilities | 18.7B | 21.9B | 19.6B | 41.7B | 28.5B | 38.9B | 2.89B | 2.06B | 1.83B |
| Shareholders' equity | 53.6B | 77.8B | 71.5B | 49.7B | 87.9B | 34.5B | 30.9B | 10.8B | 13.2B |
| Shares outstanding | 13.1M | 13.1M | 9.11M | 5.88M | 6.84M | 3.89M | 3.81M | 3.22M | 3.21M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23.4B | -27.8B | -24.9B | -21.0B | -8.44B | -7.98B | -2.51B | -2.03B | -1.57B |
| Capital spending | -75.9M | -583.6M | -16.4B | -4.14B | -952.7M | -12.0B | -427.2M | -156.8M | -602.7M |
| Free cash flow | -23.5B | -28.3B | -41.3B | -25.9B | -9.42B | -26.8B | -2.96B | -2.19B | -2.17B |
| Cash from investing | -67.6B | 16.7B | 7.16B | 6.45B | -26.5B | -26.2B | -160.8M | 11.5B | |
| Cash from financing | 39.5B | 22.9B | 1.02B | 50.7B | 42.3B | 23.3B | 19.4M | -18.6M | |
| Share buybacks | 40.0B | 45.0B | 50.0M | 73.5B | 826.5M | 23.6B | 25.3M | 99.3M | |
| Change in cash | 2.03B | -55.8B | 14.8B | -12.7B | 48.8B | 7.90B | -5.39B | -2.15B | 9.89B |
Cap table
Built by 6ix from CJ Bioscience. Inc.’s releases
- Common shares
- 13,065,462
- Fully diluted
- 13,065,462
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 13,065,462 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 13,065,462 |
Log in to ask 6ix AI your own questions about CJ Bioscience. Inc.